10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2022 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 24, 2023) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Cash Flows from Operating Activities of Continuing Operations | |||
| Net income from continuing operations | $ 14,526 | 12,358 | 4,523 |
| Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations: | |||
| Amortization | 2,085 | 1,636 | 1,817 |
| Depreciation | 1,824 | 1,578 | 1,669 |
| Intangible asset impairment charges | 1,749 | 302 | 1,718 |
| Loss (income) from investments in equity securities, net | 1,419 | (1,940) | (1,338) |
| Charge for the acquisition of Pandion Therapeutics, Inc. | 0 | 1,556 | 0 |
| Charge for the acquisition of VelosBio Inc. | 0 | 0 | 2,660 |
| Deferred income taxes | (1,568) | 187 | (566) |
| Share-based compensation | 541 | 479 | 441 |
| Other | 1,301 | 805 | 1,294 |
| Net changes in assets and liabilities: | |||
| Accounts receivable | (644) | (2,033) | (1,002) |
| Inventories | (161) | (674) | (895) |
| Trade accounts payable | (289) | 405 | 684 |
| Accrued and other current liabilities | (50) | 277 | (1,152) |
| Income taxes payable | 380 | (540) | 814 |
| Noncurrent liabilities | (545) | 484 | (617) |
| Other | (1,473) | (1,758) | (2,433) |
| Net Cash Provided by Operating Activities of Continuing Operations | 19,095 | 13,122 | 7,617 |
| Cash Flows from Investing Activities of Continuing Operations | |||
| Capital expenditures | (4,388) | (4,448) | (4,429) |
| Purchase of Seagen Inc. common stock | 0 | 0 | (1,000) |
| Purchases of securities and other investments | (1,204) | (1) | (95) |
| Proceeds from sales of securities and other investments | 721 | 1,026 | 2,812 |
| Acquisition of Acceleron Pharma Inc., net of cash acquired | 0 | (11,174) | 0 |
| Acquisition of Pandion Therapeutics, Inc., net of cash acquired | 0 | (1,554) | 0 |
| Acquisition of VelosBio Inc., net of cash acquired | 0 | 0 | (2,696) |
| Acquisition of ArQule, Inc., net of cash acquired | 0 | 0 | (2,545) |
| Other acquisitions, net of cash acquired | (121) | (179) | (1,365) |
| Other | 32 | (91) | 125 |
| Net Cash Used in Investing Activities of Continuing Operations | (4,960) | (16,421) | (9,193) |
| Cash Flows from Financing Activities of Continuing Operations | |||
| Net change in short-term borrowings | 0 | (3,986) | 2,549 |
| Payments on debt | (2,251) | (2,319) | (1,957) |
| Proceeds from issuance of debt | 0 | 7,936 | 4,419 |
| Distribution from Organon & Co. | 0 | 9,000 | 0 |
| Purchases of treasury stock | 0 | (840) | (1,281) |
| Dividends paid to stockholders | (7,012) | (6,610) | (6,215) |
| Proceeds from exercise of stock options | 384 | 202 | 89 |
| Other | (240) | (286) | (436) |
| Net Cash (Used in) Provided by Financing Activities of Continuing Operations | (9,119) | 3,097 | (2,832) |
| Cash Flows from Discontinued Operations | |||
| Net cash provided by operating activities | 0 | 987 | 2,636 |
| Net cash used in investing activities | 0 | (134) | (250) |
| Net cash used in financing activities | 0 | (504) | 0 |
| Net Cash Flows Provided by Discontinued Operations | 0 | 349 | 2,386 |
| Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | (410) | (133) | 253 |
| Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash | 4,606 | 14 | (1,769) |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $71, $103 and $258 of restricted cash at January 1, 2022, 2021 and 2020 included in Other current assets) | 8,167 | 8,153 | |
| Less: Cash and cash equivalents related to discontinued operations | 0 | 0 | 12 |
| Cash, Cash Equivalents and Restricted Cash at End of Year (includes $79, $71 and $103 of restricted cash at December 31, 2022, 2021 and 2020 included in Other current assets) | 12,773 | 8,167 | 8,153 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2022 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |